NEUTROPENIA and Potassium


NEUTROPENIA Symptoms and Causes

Your blood is living tissue made up of liquid and solids. The liquid part, called plasma, is made of water, salts and protein. Over half of your blood is plasma. The solid part of your blood contains red blood cells, white blood cells and platelets.

Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. They can be acute or chronic. Many blood disorders are inherited. Other causes include other diseases, side effects of medicines, and a lack of certain nutrients in your diet.

Types of blood disorders include

  • Platelet disorders, excessive clotting, and bleeding problems, which affect how your blood clots
  • Anemia, which happens when your blood does not carry enough oxygen to the rest of your body
  • Cancers of the blood, such as leukemia and myeloma
  • Eosinophilic disorders, which are problems with one type of white blood cell.

Check out the latest treatments for NEUTROPENIA

NEUTROPENIA treatment research studies

Potassium clinical trials, surveys and public health registries

Find Drug Side Effect reports

Potassium Side Effects

Hyperkalaemia (64)
Nausea (46)
Pain (45)
Dyspnoea (43)
Dizziness (42)
Asthenia (41)
Fatigue (37)
Cardiac Arrest (34)
Diarrhoea (32)
Completed Suicide (29)
Renal Failure (28)
Vomiting (28)
Oedema Peripheral (27)
Anxiety (26)
Chest Pain (26)
Muscle Spasms (25)
Pain In Extremity (25)
Death (24)
Fall (24)
Pyrexia (23)
Headache (22)
Weight Decreased (22)
Blood Potassium Increased (21)
Hypersensitivity (21)
Arthralgia (20)
Renal Failure Acute (20)
Abdominal Pain (19)
Cough (19)
Hypotension (19)
Injury (19)
Pneumonia (18)
Dehydration (18)
Back Pain (18)
Abdominal Pain Upper (18)
Anaemia (17)
Confusional State (17)
Depression (17)
Hypertension (17)
Malaise (17)
Overdose (17)
Cerebrovascular Accident (16)
Hypokalaemia (16)
Respiratory Failure (15)
Rash (15)
Injection Site Pain (15)
Cardiac Failure Congestive (15)
Blood Potassium Decreased (14)
Feeling Abnormal (14)
Product Quality Issue (14)
Thrombocytopenia (14)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

NEUTROPENIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
Condition: Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
Interventions: Drug: lipegfilgrastim;   Drug: pegfilgrastim
Outcome Measures: Duration of severe Neutropenia (DSN) ANC <0.5 * 10^9/L;   Incidence of febrile Neutropenia (FN) (strict definition);   Incidence of FN;   Incidence of very severe Neutropenia;   Incidence of infections;   Time to ANC recovery;   Summary of participants with adverse events
2 Recruiting Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy
Condition: Non-hematologic Cancer
Outcome Measures: Identify predictive models about the risk of febrile Neutropenia and Neutropenia grade 3/4 in patients with non-hematologic cancer;   Occurrence of serious adverse events;   Analyze costs to treat febrile Neutropenia and Neutropenia grade 3/4;   Analyze the risk of mortality due to febrile Neutropenia and Neutropenia grade 3/4 during the chemotherapy treatment;   Evaluate impact of febrile Neutropenia and Neutropenia grade 3/4 in treatment compliance
3 Recruiting Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
Conditions: Septic Shock;   Nonchemotherapy Drug-induced Neutropenia;   Neutropenia After Chemotherapy in Oncohematological Patients;   Neutropenia in Patients With Aplastic Anemia
Interventions: Genetic: Mesenchymal stromal cells;   Drug: Standard therapy of septic shock
Outcome Measures: mortality;   Evaluation of MSC therapy effects on organ dysfunction;   Evaluation of MSC therapy effects on systemic inflammatory parameters;   Evaluation of MSC therapy effects on septic shock reversal
4 Recruiting Study of Danggui Buxue Decoction in Preventing Neutropenia
Conditions: Grade 3/4 Neutropenia;   Febrile Neutropenia
Interventions: Drug: DBD;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
Outcome Measures: incidence of grade 3/4 Neutropenia;   times of grade 3/4 Neutropenia per cycle of chemotherapy;   incidence of febrile Neutropenia;   the time to Neutropenia recovery
5 Recruiting A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
Conditions: NSCLC;   Neutropenia;   Febrile Neutropenia
Interventions: Drug: Pegylated rhG-CSF: 100µg/kg;   Drug: Pegylated rhG-CSF: 6mg;   Drug: placebo and rhG-CSF 5ug/kg/d
Outcome Measures: Rate of grade 3/4 Neutropenia in cycle 1;   Incidence of febrile Neutropenia in cycle 1;   Rate of grade 3/4 Neutropenia and incidence of febrile Neutropenia in cycle 2 to 4;   Time to neutrophil recovery in the 4 chemotherapy cycles;   Duration of 3/4 Neutropenia in the 4 chemotherapy cycles;   Objective response rate;   Progress free survival;   Overall survival;   Exploratory biomarkers research
6 Not yet recruiting Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
Conditions: Febrile Neutropenia;   Hematological Malignancy
Intervention: Drug: Discontinuation of imipenem-cilastatin or meropenem
Outcome Measures: The percentage of patients with failed treatment;   All-cause mortality;   Infection-related mortality;   The length of hospitalization in days;   Unexpected re-admission other than for planned chemotherapy or other elective treatment.;   The recurrence of fever within 24 hours after discontinuation of antibiotic therapy.;   The total number of febrile episodes during Neutropenia;   Time to defervescence;   Antibiotic or antifungal treatment within 30days after discharge other than standard antibiotic prophylaxis.;   Incidence and prevalence of Clostridium difficile infection;   Incidence and prevalence of liver and kidney dysfunction;   Candida spp. colonization in (surveillance) cultures;   Cost of antimicrobial therapy per admission;   MASCC-score;   The percentage of patients with mucositis and positive blood cultures or short treatment failure.;   Bacterial resistance in blood cultures and surveillance cultures (including minimal inhibitory concentrations (MIC)).
7 Recruiting A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
Conditions: Stage III Colorectal Cancer;   Neutropenia
Interventions: Drug: MB-6;   Drug: Placebo
Outcome Measures: The primary endpoint is the incidence of grade 4 Neutropenia during the chemotherapy period, defined as an absolute neutrophil count (ANC) <500/mm3.;   Time to first Grade 4 Neutropenia;   Incidence of Febrile Neutropenia;   Incidence of Grade 3 or 4 Neutropenia;   Change in Serum Creatinine level;   Health-Related Quality of Life (HRQoL) - QLQ-C30;   Quality of Life -VAS on Fatigue, Constipation, Appetite;   Compliance with Chemotherapy;   Increase in Body Weight
8 Recruiting Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
Condition: Neutropenia
Interventions: Drug: pegfilgrastim,30mcg/kg;   Drug: pegfilgrastim, 60mcg/kg;   Drug: pegfilgrastim, 100mcg/kg;   Drug: filgrastim, 5mcg/kg
Outcome Measures: Duration of ≥grade 3 Neutropenia in cycle 2;   change of Neutropenia and ANC in cycle 2
9 Recruiting Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia
Condition: Febrile Neutropenia
Interventions: Other: Empirical antimicrobial treatment discontinuation;   Other: Standard empirical antimicrobial treatment discontinuation
Outcome Measures: Number of days on which patient is free of antimicrobial treatment;   Crude mortality;   Number of days of fever
10 Unknown  Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
Conditions: Brain and Central Nervous System Tumors;   Lymphoma;   Neutropenia;   Psychosocial Effects of Cancer and Its Treatment;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: amoxicillin-clavulanate potassium;   Drug: ciprofloxacin;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Outcome Measures: Total number of days of hospitalization (including unplanned readmission) (randomized patients);   Incidence of serious adverse events (randomized and registered patients);   Incidence of treatment failure as defined by the necessity for change in antibiotic therapy (randomized and registered patients);   Incidence of unplanned readmissions (randomized patients);   Patient acceptability of randomized discharge policy as measured by Health Questionnaire, Cancer Worries Inventory Booklet, and Patient Daily Diary (randomized patients);   Toxicity attributed to oral antibiotic therapy as measured by NCI CTCAE v3.0 (randomized and registered patients);   Health service costs (randomized patients)
11 Recruiting Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Outcome Measures: Risk prediction model for grade 3-4 chemotherapy induced Neutropenia;   The association between mannose-binding lectin 2 gene SNP and Neutropenia
12 Recruiting Garlic in Patients With Febrile Neutropenia
Conditions: Chemotherapy;   Neutropenia
Interventions: Dietary Supplement: Solgar Israel;   Other: Placebo capsules
Outcome Measures: Time to fever and beginning of empiric antibiotic treatment.;   Documented and culture positive infections.;   Kind of infectious organisms and sensitivity to medicines.;   Length of infection;   Use of growth factors.
13 Unknown  A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy
Conditions: Breast Cancer;   Chemotherapy;   Neutropenia
Intervention: Other: EW02
Outcome Measures: % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in WBC,;   % change from Visit 5 (C2, Day 1) to Visit 7 (C2, Day 15) in ANC;   QOL analysis using EORTC questionnaires ndex scores;   Inter-group comparison of Quality of Life survey collected for Cycle 2;   Within group analysis (based on "same person comparison"), on the change of WBC/ANC and QOL index scores
14 Recruiting Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients
Condition: Neutropenia
Interventions: Drug: HM10460A (45 μg/kg);   Drug: HM10460A (135 μg/kg);   Drug: HM10460A (270 μg/kg);   Drug: Pegfilgrastim 6mg
Outcome Measures: Duration of severe Neutropenia (DSN) in Cycle 1;   Effect of Test Doses of HM10460A
15 Unknown  Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Conditions: Febrile Neutropenia;   Cancer;   Breast Cancer;   Ovarian Cancer;   Lung Cancer;   Prostate Cancer;   Multiple Myeloma;   Bladder Cancer;   B-cell Lymphoma
Outcome Measures: Absolute neutrophil count (ANC);   Cohort identification and differentiation;   Nonresponder analyses
16 Unknown  Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy
Condition: Neutropenia
Interventions: Drug: late leukostim;   Drug: early leukostim
Outcome Measure: frequency of Neutropenia
17 Unknown  Registry of Febrile Neutropenia and Invasive Fungal Infections
Conditions: Hematological Disease;   Febrile Neutropenia;   Fungal Infections
Intervention: Other: Patient registry
Outcome Measure:
18 Unknown  International Registry for Severe Chronic Neutropenia
Condition: Neutropenia
Outcome Measure:
19 Recruiting Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Conditions: Underdose (Unintentional);   Cancer;   Tumor
Intervention: Drug: rHSA/GCSF
Outcome Measures: Number of adverse events;   AUC
20 Recruiting Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Conditions: Non Small Cell Lung Cancer;   Breast Cancer
Interventions: Drug: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle;   Drug: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle;   Drug: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle;   Drug: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
Outcome Measures: Incidence of Grade 3 &4 Neutropenia, and median duration of Neutropenia in the two experimental cycles;   Incidence of febrile Neutropenia in the two experimental cycles;   Diversification of neutrophil in the two experimental cycles